news & events




July 2018

AROMICS completes the project on liquid biopsy CTC predict

AROMICS has successfully completed its project entitled CTC-predict: "Development of a drug screening platform based on circulating tumor cell". The project is integrated into the general strategy of the company in the ​​oncology area that has two main objectives: (a) the development of new drugs that are more effective and safer;...


May 2018

AROMICS to participate at the Genesis Drug Discovery meeting in Barcelona 10-11 May 2018

Dr.Carmen Plasencia, CEO of AROMICS one of the speakers on the 2nd Genesis Drug Discovery (GDD) that will take place in Barcelona 10 and 11th May 2018. The speech will focus on the involvment of metabolic routes in cancer and will allow the company to present its latest advances...


April 2018

Berberine derivatives are present at IX WDD-2018 Congress

Dr. Paolo Lombardi, CEO of Naxospharma and former collaborator of AROMICS will present the advances of Berberine and novel derivatives as therapy for treating cancer. Dr. Lombardi is one of the participants of the World DNA Day, the most influential congress that BIT organized in the past 14 years. The aim of BIT's 9th...


March 2018

AROMICS to participate at the annual meeting of the International Mesothelioma Group iMig in Ottawa, Canada

AROMICS will be present on the 14th meeting of the International Mesothelioma Interest Group (iMig 2018) to be held in Ottawa, Canada in May 2018. During the congress the company will present new data with the compound NAX035, on the mechanism of action and preclinical efficacy in experimental models of mesothelioma. The work presented...

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9